Wang Peng, Xiao Pei, Ye Yingnan, Liu Pengpeng, Han Lei, Dong Li, She Chunhua, Yu Jinpu
Department of Neuro-Oncology.
Cancer Biol Med. 2017 May;14(2):183-186. doi: 10.20892/j.issn.2095-3941.2017.0017.
Non-small cell lung cancer (NSCLC) ranks as the leading cause of cancer-related death in the world. Brain metastasis (BM) is a common complication of NSCLC, with 25%-40% of patients developing BM during the course of the disease. A significant strategy of local disease control in the central nervous system is radiation therapy. With the development of precision medicine, the concept of treating lung cancer BM has gradually changed. In this case, we performed a surgical procedure to obtain enough tumor tissue for the detection of the target gene and other related experiments after the patient was informed. Finally, we found that the patient had both hepatocyte growth factor receptor (MET) gene amplification and kinesin light chain 1-anaplastic lymphoma kinase fusion (KLC1-ALK) through next-generation sequencing and showed sensitivity to the targeted therapy of crizotinib. The patient exhibited good response. Our case was successful and underwent targeted therapy with the guidance of precise diagnosis.
非小细胞肺癌（NSCLC）是全球癌症相关死亡的主要原因。脑转移（BM）是NSCLC的常见并发症，25%-40%的患者在疾病过程中会发生BM。放射治疗是中枢神经系统局部疾病控制的重要策略。随着精准医学的发展，肺癌BM的治疗理念逐渐发生变化。在此病例中，我们在告知患者后进行了手术，以获取足够的肿瘤组织用于检测靶基因和其他相关实验。最后，通过下一代测序我们发现该患者既有肝细胞生长因子受体（MET）基因扩增，又有驱动蛋白轻链1-间变性淋巴瘤激酶融合（KLC1-ALK），并对克唑替尼靶向治疗敏感。患者表现出良好反应。我们的病例取得成功，并在精确诊断的指导下接受了靶向治疗。
